Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer

Related Experiment Video

Updated: Mar 5, 2026

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

43.0K

Doudou Huang1, Fang Yang1, Yucai Wang2

  • 1Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, PR China.

Biochimica Et Biophysica Acta. Reviews on Cancer
|March 28, 2017
PubMed

Insights

Fulvestrant effectively treats ER-positive breast cancer but resistance can develop. Combining fulvestrant with targeted therapies may overcome resistance and improve treatment outcomes for patients.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Estrogen receptor (ER) signaling is crucial in breast cancer, leading to the development of endocrine therapies.
  • Fulvestrant, a selective ER down-regulator (SERD), is effective but resistance limits its long-term efficacy.
  • Mechanisms of fulvestrant resistance include ERα-independent signaling and altered cell cycle regulation.

Purpose of the Study:

  • To review the mechanisms of fulvestrant resistance in ER-positive breast cancer.
  • To explore combination strategies of fulvestrant with targeted agents.
  • To provide insights into optimal therapeutic approaches for resistant breast cancer.

Main Methods:

  • Literature review of studies on fulvestrant resistance mechanisms.
  • Analysis of experimental data on combination therapies.
  • Overview of ongoing clinical trials for targeted combination therapies.

Main Results:

  • Fulvestrant resistance arises from various pathways, including compensatory growth factor signaling.
  • Combining fulvestrant with targeted treatments shows promise in overcoming resistance.
  • Clinical trials are evaluating the efficacy of these combination therapies.

Conclusions:

  • Understanding fulvestrant resistance mechanisms is key to developing effective treatments.
  • Combination therapy with targeted agents offers a promising strategy for ER-positive breast cancer.
  • Further research and clinical trials are needed to optimize treatment for resistant breast cancer.
Keywords:
Estrogen receptor-positive metastatic breast cancerFulvestrant resistanceMechanismTargeted combination therapy

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

11.0K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.7K

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
4.2K